Oncology

Yet another clinical hold for Gilead’s magrolimab trials

Gilead Sciences had paused enrolment in the magrolimab solid tumour trials, with the FDA requesting a partial clinical hold on…

BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets

BioVaxys Technology has acquired the entire portfolio of discovery, preclinical and clinical assets along with the corresponding intellectual assets from…

Q4 2023 update: immuno-oncology related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 14 pharmaceutical deals announced in Q4 2023,…

CAR-T therapies and cancer risk: No easy answers for the FDA

Chimeric antigen receptor (CAR)-T cell therapies have always carried a risk of causing secondary malignancies, but until now that risk…

Gilead’s Tecartus escapes harsher classwide boxed warning for CAR-T therapies

A few days after the US FDA issued letters seeking the addition of black box warnings of secondary T-cell malignancies,…

OSE shares pipeline updates and plans Phase III trial for Tedopi

The French company OSE Immunotherapeutics has provided an update for its clinical pipeline, with plans to start a confirmatory Phase…

TiumBio raises $12m to advance clinical pipeline development

South Korean TiumBio has raised KRW20bn ($12m) through stock financing to fund the development of its clinical programmes. The capital…

BMS bags advanced melanoma win for Opdualag in the UK

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced the approval of Bristol Myers Squibb’s Opdualag (nivolumab and relatlimab)…

Kronos Bio swivels focus towards multiple myeloma after AML failure

Kronos Bio has declared that it will not be continuing clinical development for its acute myeloid leukaemia (AML) spleen tyrosine…

Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery

Daiichi Sankyo has partnered with a French startup Depixus to accelerate its RNA-targeted drug discovery programme The collaboration will leverage…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close